Microglial Contributions to Huntington's Disease Pathogenesis

📖 Wiki Page

experiment752 wordssynced 2026-04-02

Microglial Contributions to Huntington's Disease Pathogenesis

Hypothesis

flowchart TD experiments_microglial_immune_["Microglial Contributions to Huntingtons Disease"] style experiments_microglial_immune_ fill:#4fc3f7,stroke:#333,color:#000 experiments_microgli_0["Hypothesis"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_0 style experiments_microgli_0 fill:#81c784,stroke:#333,color:#000 experiments_microgli_1["Gap Addressed"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_1 style experiments_microgli_1 fill:#ef5350,stroke:#333,color:#000 experiments_microgli_2["Evidence for Microglial Involvement in HD"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_2 style experiments_microgli_2 fill:#ffd54f,stroke:#333,color:#000 experiments_microgli_3["Key Microglial Pathways in HD"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_3 style experiments_microgli_3 fill:#ce93d8,stroke:#333,color:#000 experiments_microgli_4["Experimental Design"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_4 style experiments_microgli_4 fill:#4fc3f7,stroke:#333,color:#000 experiments_microgli_5["Aim 1: Single-Cell Microglial Phenotyping"] experiments_microglial_immune_ -->|"includes"| experiments_microgli_5 style experiments_microgli_5 fill:#81c784,stroke:#333,color:#000

...

Microglial Contributions to Huntington's Disease Pathogenesis

Hypothesis

Mermaid diagram (expand to render)

Microglia in HD adopt both neuroprotective (surveillance, debris clearance) and neurotoxic (pro-inflammatory, phagocytic over-activation) phenotypes depending on disease stage and genetic context. The balance between these states determines whether microglia promote or protect against neurodegeneration.

Gap Addressed

HD Knowledge Gap #8 (Score: 28): Microglial and immune contributions in HD — addresses the role of microglia in HD progression and whether modulating microglial activity can slow neurodegeneration.

Background

Evidence for Microglial Involvement in HD

PET imaging: Increased TSPO binding in HD striatum and cortex, indicating microglial activation
CSF biomarkers: Elevated YKL-40 (chitinase-3-like protein) in HD, correlating with disease progression
Post-mortem: Increased IBA1+ microglia with morphological changes in HD brain
Genetic links: MS4A14, HLA variants modify HD age of onset

Key Microglial Pathways in HD

TREM2 signaling: Variants associated with HD progression rate
Complement system: C1q, C3 overactivation leading to synapse loss
NLRP3 inflammasome: IL-1β, IL-18 overproduction
CX3CR1 signaling: Fractalkine receptor dysregulation

Experimental Design

Aim 1: Single-Cell Microglial Phenotyping

Approach: Characterize microglial heterogeneity across HD progression using single-cell approaches

Model System:

Post-mortem brain tissue (striatum, cortex) from HD patients at multiple disease stages
BACHD and Q175 mouse models at pre-symptomatic, early, and late stages
iPSC-derived microglia from HD patients

Assays:

Single-nucleus RNA-seq: Transcriptomic profiling of microglial nuclei
Single-cell ATAC-seq: Chromatin accessibility in microglia
Spatial transcriptomics: Microglial distribution relative to neurons and pathology

Phenotypes to Characterize:

Surveillance microglia: Resting state, homeostatic markers (P2RY12, TMEM119)
DAM (disease-associated microglia): TREM2-dependent, lipid metabolism genes
Aging-associated microglia: IFN-responsive, complement activation
Müller glia-like: Alternative activation state

Key Questions:

When do microglia transition from protective to harmful phenotypes?
Which microglial pathways correlate with disease progression?
Are there microglial subtypes that predict disease trajectory?

Aim 2: Causal Role of Microglial Dysfunction

Approach: Test whether microglial activation is a driver or consequence of neurodegeneration

Genetic Approaches:

Conditional knock-out: Remove mHTT specifically from microglia using CX3CR1-Cre

TREM2 knock-out: Cross HD mice with TREM2-/- to test TREM2 dependency

Complement deficiency: Remove C1q or C3 to test synapse protection

Pharmacological Approaches:

CSF1R inhibition: PLX3397, PLX5622 to deplete microglia

TREM2 agonism: TREM2-activating antibodies

NLRP3 inhibitors: MCC950 to block inflammasome

CX3CR1 agonists: Fractalkine supplementation

Readouts:

Neuronal survival (cell counts, electrophysiology)
mHTT aggregation (biochemistry, histology)
Behavioral rescue (rotarod, grip strength, open field)
Synaptic integrity (dendritic spines, PSD95 density)

Aim 3: Microglia-Neuron Communication

Approach: Define how microglia communicate with neurons in HD

Communication Pathways:

Complement-mediated synapse elimination: C1q tagging, C3-CR3 signaling

Cytokine signaling: IL-1β, TNF-α effects on neuronal function

Growth factor modulation: BDNF dysregulation by microglia

Extracellular vesicle signaling: microRNA transfer

Experimental Systems:

[Microglia](/cell-types/microglia)neuron co-cultures (iPSC-derived)
Organotypic brain slices
In vivo two-photon imaging of microglia-synapse interactions

Readouts:

Synapse elimination rates (time-lapse imaging)
Neuronal transcriptome changes (snRNA-seq after microglial depletion)
Electrophysiological properties

Aim 4: Therapeutic Targeting

Approach: Test microglia-modifying therapies in HD models

Therapeutic Candidates:

TREM2-modulating antibodies (currently in AD trials)

CSF1R inhibitors (already in HD clinical trials)

Anti-IL-1 therapies (anakinra, canakinumab)

Complement inhibitors (C1q, C3 blockers)

Minocycline (broad anti-inflammatory, tested in HD)

Model System:

BACHD mice (early intervention)
Q175 mice (late intervention)
Humanized models for cross-species translation

Endpoints:

Behavioral rescue
Neuroimaging (MRI, PET)
Biomarker modulation (YKL-40, NfL)

Expected Outcomes

Microglial atlas — Detailed characterization of microglial phenotypes across HD progression

Causal mechanisms — Determine whether microglia drive or respond to neurodegeneration

Communication pathways — Map microglia-neuron signaling in HD

Therapeutic targets — Identify microglia-modifying therapies that slow HD progression

Feasibility and Cost

| Component | Estimated Cost | Timeline |
|-----------|----------------|----------|
| Aim 1: Single-cell profiling | $1.8M | 18 months |
| Aim 2: Causal validation | $2.0M | 24 months |
| Aim 3: Communication mapping | $1.5M | 18 months |
| Aim 4: Therapeutic testing | $2.2M | 24 months |
| Total | $7.5M | 36 months |

Risk Assessment

Technical risk: Medium — single-cell technologies established; mouse models available
Complexity: High — microglial heterogeneity requires careful interpretation
Translation risk: Mouse-to-human differences in microglial biology

References

[Ferrante et al., Neuroinflammation in HD (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)

[HDCytes Consortium, Cell-type specific vulnerability in HD (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Ferrante et al., Striatal vulnerability in HD (2023)](https://pubmed.ncbi.nlm.nih.gov/37289012/)

[Tabrizi et al., Huntington disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37252945/)

[Kieburtz et al., Tominersen trial outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

📖 View canonical wiki page →